Organogenesis Q2 revenue down 23% to $100.8M; amends credit agreement, waives covenant test

Organogenesis Holdings Inc.

2025-Q2 EPS reported -$0.27 revenue$187,698,000

Net product revenue $100.8M (down 23% YoY); Advanced Wound Care fell 25%, Surgical & Sports Med up 16%.
Net loss $9.4M ($0.10 per share) vs $17.0M loss a year ago; adjusted net loss $7.5M vs income $0.2M.
FY2025 guidance: revenue $480-510M (flat to +6%); adjusted EBITDA $31.1-61.9M.
Fourth Amendment to Credit Agreement waives Q2 2025 covenant test; must reset covenants by Sept 30, 2025; no additional borrowing until then.
Cash and restricted cash $73.7M, no debt; expects cash plus product sales to fund ops for 12 months.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.